Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.860
-0.070 (-2.39%)
Aug 14, 2025, 11:47 AM - Market open
Vistagen Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Cash & Equivalents | 48.99 | 67.13 | 119.17 | 16.64 | 68.14 | 103.11 | Upgrade
|
| Short-Term Investments | 14.2 | 13.35 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 63.18 | 80.48 | 119.17 | 16.64 | 68.14 | 103.11 | Upgrade
|
| Cash Growth | -41.70% | -32.46% | 616.23% | -75.58% | -33.92% | 7508.91% | Upgrade
|
| Other Receivables | - | - | - | - | 0.34 | 0.04 | Upgrade
|
| Receivables | - | - | - | - | 0.34 | 0.04 | Upgrade
|
| Prepaid Expenses | 3.54 | 1.59 | 1.51 | 0.8 | 0.2 | 0.12 | Upgrade
|
| Other Current Assets | - | - | - | 0.07 | 2.33 | 0.85 | Upgrade
|
| Total Current Assets | 66.72 | 82.08 | 120.67 | 17.51 | 71 | 104.12 | Upgrade
|
| Property, Plant & Equipment | 1.74 | 1.81 | 2.26 | 2.77 | 3.08 | 3.59 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | 0.71 | 0.47 | 0.53 | Upgrade
|
| Other Long-Term Assets | 0.47 | 0.45 | 0.73 | 0.1 | 0.1 | 0.05 | Upgrade
|
| Total Assets | 68.92 | 84.34 | 123.65 | 21.09 | 74.64 | 108.28 | Upgrade
|
| Accounts Payable | 0.49 | 0.65 | 1.55 | 2.47 | 2.76 | 0.84 | Upgrade
|
| Accrued Expenses | 6.58 | 8.81 | 2.24 | 0.8 | 1.33 | 1.56 | Upgrade
|
| Short-Term Debt | 0.93 | - | - | 0.11 | - | - | Upgrade
|
| Current Portion of Leases | 0.64 | 0.56 | 0.55 | 0.49 | 0.43 | 0.37 | Upgrade
|
| Current Unearned Revenue | 2.51 | 2.59 | 0.79 | 0.71 | 1.24 | 1.42 | Upgrade
|
| Total Current Liabilities | 11.16 | 12.61 | 5.12 | 4.57 | 5.77 | 4.19 | Upgrade
|
| Long-Term Leases | 0.78 | 0.95 | 1.57 | 2.12 | 2.61 | 3.35 | Upgrade
|
| Long-Term Unearned Revenue | 0.22 | 0.39 | 2.67 | 2.32 | 1.56 | 2.49 | Upgrade
|
| Total Liabilities | 12.16 | 13.95 | 9.37 | 9.01 | 9.93 | 10.03 | Upgrade
|
| Common Stock | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | 0.18 | Upgrade
|
| Additional Paid-In Capital | 483.43 | 481.96 | 474.44 | 342.89 | 336.28 | 315.6 | Upgrade
|
| Retained Earnings | -422.73 | -407.63 | -356.21 | -326.85 | -267.6 | -219.84 | Upgrade
|
| Treasury Stock | -3.97 | -3.97 | -3.97 | -3.97 | -3.97 | -3.97 | Upgrade
|
| Comprehensive Income & Other | 0 | 0.01 | - | - | - | - | Upgrade
|
| Total Common Equity | 56.77 | 70.39 | 114.29 | 12.08 | 64.72 | 91.97 | Upgrade
|
| Shareholders' Equity | 56.77 | 70.39 | 114.29 | 12.08 | 64.72 | 98.25 | Upgrade
|
| Total Liabilities & Equity | 68.92 | 84.34 | 123.65 | 21.09 | 74.64 | 108.28 | Upgrade
|
| Total Debt | 2.36 | 1.51 | 2.12 | 2.71 | 3.04 | 3.72 | Upgrade
|
| Net Cash (Debt) | 60.82 | 78.97 | 117.05 | 13.93 | 65.1 | 99.39 | Upgrade
|
| Net Cash Growth | -42.82% | -32.53% | 740.43% | -78.61% | -34.50% | - | Upgrade
|
| Net Cash Per Share | 1.95 | 2.56 | 6.05 | 2.00 | 9.86 | 34.62 | Upgrade
|
| Filing Date Shares Outstanding | 30.68 | 29.16 | 27.03 | 7.87 | 6.89 | 6.38 | Upgrade
|
| Total Common Shares Outstanding | 29.28 | 29 | 27.03 | 7.31 | 6.88 | 6.02 | Upgrade
|
| Working Capital | 55.56 | 69.46 | 115.55 | 12.93 | 65.23 | 99.93 | Upgrade
|
| Book Value Per Share | 1.94 | 2.43 | 4.23 | 1.65 | 9.40 | 15.28 | Upgrade
|
| Tangible Book Value | 56.77 | 70.39 | 114.29 | 12.08 | 64.72 | 91.97 | Upgrade
|
| Tangible Book Value Per Share | 1.94 | 2.43 | 4.23 | 1.65 | 9.40 | 15.28 | Upgrade
|
| Machinery | - | 1.6 | 1.48 | 1.49 | 1.45 | 1.29 | Upgrade
|
| Leasehold Improvements | - | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 | Upgrade
|
Updated Jun 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.